
David M. Brown, MD, is Clinical Professor of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine and vice-chair for research at the Blanton Eye Institute, Houston Methodist Hospital. He is the Director of Clinical Research at the Greater Houston Retina Research Center and in private practice at Retina Consultants of Houston. Dr. Brown graduated from Baylor College of Medicine with highest honors and completed ophthalmology and retina training at the University of Iowa where he was a Thomas Heed Fellow, a Hermann Knapp Fellow, and was awarded the Ron Michels Fellowship award presented to the top retinal surgery fellow in the US.
Dr Brown’s research and clinical interests are focused on macular surgery, AMD, gene therapy, retinal vascular disease, and diabetic retinopathy. Dr. Brown is an elected member of the Macula Society and the Retina Society and he directs one of the largest clinical trial centers for retinal disease in the US. Dr. Brown’s honors include the American Academy of Ophthalmology Honor Award in 2000, the AAO Senior Honor Award in 2014, and continuous election as one of the “Best Doctors in America” 2007 -2017. He has published and written over 400 national meeting presentations, abstracts, and scientific papers including many of the primary papers establishing the use of anti-VEGF agents for AMD, retinal vein occlusions, and diabetic retinopathy.
Financial disclosure: I have/had an affiliation (financial or otherwise) with a commercial organization:
Dr Brown’s research and clinical interests are focused on macular surgery, AMD, gene therapy, retinal vascular disease, and diabetic retinopathy. Dr. Brown is an elected member of the Macula Society and the Retina Society and he directs one of the largest clinical trial centers for retinal disease in the US. Dr. Brown’s honors include the American Academy of Ophthalmology Honor Award in 2000, the AAO Senior Honor Award in 2014, and continuous election as one of the “Best Doctors in America” 2007 -2017. He has published and written over 400 national meeting presentations, abstracts, and scientific papers including many of the primary papers establishing the use of anti-VEGF agents for AMD, retinal vein occlusions, and diabetic retinopathy.
Financial disclosure: I have/had an affiliation (financial or otherwise) with a commercial organization:
- Bayer
- Regeneron
- Senju
- Adverum
- Regenxbio
- OHR Pharmaceutical Inc.
- Boehringer Ingelheim
- Novartis
- Heidelberg
- OPTOS
- Stealth Biotherapeutics
- Biotime
- Samsung
- Roche
- Genentech
- ChengduKanghong Biotechnology
- Merck
- Apellis
- Spark
- Allergan
- Clearside
- Tyrogenex
- National Eye Institute
- Opthotech
Sessions in which David M. Brown MD, FACS participates
Saturday 2 June, 2018
Time Zone: (GMT-05:00) Eastern Time (US & Canada)
Sunday 3 June, 2018
Time Zone: (GMT-05:00) Eastern Time (US & Canada)
Current Concepts III
8:00 -
10:00 |
2 hours
- Yvonne Buys (Moderator)
- Steven Bellemare MD, FRCPC, CPE (Participant)
- Steven J. Gedde MD (Participant)
- Dr. Mona Harissi-Dagher (Moderator)
- Dr. Soosan Jacob, MS, FRCS, DNB, MNAMS (Participant)
- Linda R. Dagi MD (Participant)
- David M. Brown MD, FACS (Participant)
- Usha Chakravarthy MD, PhD (Participant)
- Karl Stonecipher MD (Participant)
Management of DME in 2018 - An evidence-based approach
13:35 -
13:50 |
15 minutes